Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
Huntington's disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have developed HTT gene-silencing approaches based on ex...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253117300987 |
id |
doaj-bfb13c6a50a649a182bd1d5204f6412a |
---|---|
record_format |
Article |
spelling |
doaj-bfb13c6a50a649a182bd1d5204f6412a2020-11-24T22:48:07ZengElsevierMolecular Therapy: Nucleic Acids2162-25312016-01-015C10.1038/mtna.2016.7Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's DiseaseJana Miniarikova0Ilaria Zanella1Angelina Huseinovic2Tom van der Zon3Evelyn Hanemaaijer4Raygene Martier5Annemart Koornneef6Amber L Southwell7Michael R Hayden8Sander J van Deventer9Harald Petry10Pavlina Konstantinova11Department of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, CanadaCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, CanadaDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsDepartment of Research & Development, uniQure, Amsterdam, the NetherlandsHuntington's disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have developed HTT gene-silencing approaches based on expression cassette-optimized artificial miRNAs (miHTTs). In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1. In the second approach, allele-specific silencing was induced by targeting the heterozygous single-nucleotide polymorphism (SNP) rs362331 in exon 50 or rs362307 in exon 67 linked to mtHTT. The miHTT expression cassette was optimized by embedding anti-HTT target sequences in ten pri-miRNA scaffolds and their HTT knockdown efficacy, allele selectivity, passenger strand activity, and processing patterns were analyzed in vitro. Furthermore, three scaffolds expressing miH12 targeting exon 1 were incorporated in an adeno-associated viral serotype 5 (AAV5) vector and their HTT knock-down efficiency and pre-miHTT processing were compared in the humanized transgenic Hu128/21 HD mouse model. Our data demonstrate strong allele-selective silencing of mtHTT by miSNP50 targeting rs362331 and total HTT silencing by miH12 both in vitro and in vivo. Ultimately, we show that HTT knock-down efficiency and guide strand processing can be enhanced by using different cellular pri-miRNA scaffolds.http://www.sciencedirect.com/science/article/pii/S2162253117300987adeno-associated virusgene silencinghumanized HD mouse modelHuntington's diseasetherapeutic microRNAs |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jana Miniarikova Ilaria Zanella Angelina Huseinovic Tom van der Zon Evelyn Hanemaaijer Raygene Martier Annemart Koornneef Amber L Southwell Michael R Hayden Sander J van Deventer Harald Petry Pavlina Konstantinova |
spellingShingle |
Jana Miniarikova Ilaria Zanella Angelina Huseinovic Tom van der Zon Evelyn Hanemaaijer Raygene Martier Annemart Koornneef Amber L Southwell Michael R Hayden Sander J van Deventer Harald Petry Pavlina Konstantinova Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease Molecular Therapy: Nucleic Acids adeno-associated virus gene silencing humanized HD mouse model Huntington's disease therapeutic microRNAs |
author_facet |
Jana Miniarikova Ilaria Zanella Angelina Huseinovic Tom van der Zon Evelyn Hanemaaijer Raygene Martier Annemart Koornneef Amber L Southwell Michael R Hayden Sander J van Deventer Harald Petry Pavlina Konstantinova |
author_sort |
Jana Miniarikova |
title |
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease |
title_short |
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease |
title_full |
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease |
title_fullStr |
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease |
title_full_unstemmed |
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease |
title_sort |
design, characterization, and lead selection of therapeutic mirnas targeting huntingtin for development of gene therapy for huntington's disease |
publisher |
Elsevier |
series |
Molecular Therapy: Nucleic Acids |
issn |
2162-2531 |
publishDate |
2016-01-01 |
description |
Huntington's disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have developed HTT gene-silencing approaches based on expression cassette-optimized artificial miRNAs (miHTTs). In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1. In the second approach, allele-specific silencing was induced by targeting the heterozygous single-nucleotide polymorphism (SNP) rs362331 in exon 50 or rs362307 in exon 67 linked to mtHTT. The miHTT expression cassette was optimized by embedding anti-HTT target sequences in ten pri-miRNA scaffolds and their HTT knockdown efficacy, allele selectivity, passenger strand activity, and processing patterns were analyzed in vitro. Furthermore, three scaffolds expressing miH12 targeting exon 1 were incorporated in an adeno-associated viral serotype 5 (AAV5) vector and their HTT knock-down efficiency and pre-miHTT processing were compared in the humanized transgenic Hu128/21 HD mouse model. Our data demonstrate strong allele-selective silencing of mtHTT by miSNP50 targeting rs362331 and total HTT silencing by miH12 both in vitro and in vivo. Ultimately, we show that HTT knock-down efficiency and guide strand processing can be enhanced by using different cellular pri-miRNA scaffolds. |
topic |
adeno-associated virus gene silencing humanized HD mouse model Huntington's disease therapeutic microRNAs |
url |
http://www.sciencedirect.com/science/article/pii/S2162253117300987 |
work_keys_str_mv |
AT janaminiarikova designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT ilariazanella designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT angelinahuseinovic designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT tomvanderzon designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT evelynhanemaaijer designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT raygenemartier designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT annemartkoornneef designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT amberlsouthwell designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT michaelrhayden designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT sanderjvandeventer designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT haraldpetry designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease AT pavlinakonstantinova designcharacterizationandleadselectionoftherapeuticmirnastargetinghuntingtinfordevelopmentofgenetherapyforhuntingtonsdisease |
_version_ |
1725679533200244736 |